D. E. Shaw & Co., Inc. Neurocrine Biosciences Inc Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 169,454 shares of NBIX stock, worth $22.9 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

169,454

Holding current value

$22.9 Million

% of portfolio

0.02%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$114.58 - $153.15 $7 Million - $9.35 Million	61,076 Added 56.35%	169,454 $19.5 Million
Q2 2024 Aug 14, 2024	SELL	$130.86 - $143.19 $4.83 Million - $5.28 Million	-36,902 Reduced 25.4%	108,378 $14.9 Million
Q1 2024 May 15, 2024	BUY	$130.4 - $143.74 $9.03 Million - $9.96 Million	69,278 Added 91.15%	145,280 $20 Million
Q4 2023 Feb 14, 2024	BUY	$106.07 - $132.76 $1.8 Million - $2.25 Million	16,940 Added 28.68%	76,002 $10 Million
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $17.1 Million - $21.2 Million	-181,422 Reduced 75.44%	59,062 $6.64 Million
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $5.5 Million - $6.44 Million	61,378 Added 34.27%	240,484 $22.7 Million
Q1 2023 May 15, 2023	SELL	$94.11 - $123.02 $7.52 Million - $9.83 Million	-79,937 Reduced 30.86%	179,106 $18.1 Million
Q4 2022 Feb 14, 2023	BUY	$106.72 - $127.06 $12.8 Million - $15.2 Million	119,781 Added 86.01%	259,043 $30.9 Million
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $7.41 Million - $8.68 Million	-80,475 Reduced 36.62%	139,262 $14.8 Million
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $90,644 - $119,683	-1,196 Reduced 0.54%	219,737 $21.4 Million
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $8.91 Million - $11.7 Million	122,957 Added 125.5%	220,933 $20.7 Million
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $7.8 Million - $10.4 Million	97,976 New	97,976 $8.35 Million
Q2 2021 Aug 16, 2021	SELL	$89.43 - $102.27 $780,902 - $893,021	-8,732 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$87.57 - $119.4 $100,530 - $137,071	-1,148 Reduced 11.62%	8,732 $849,000
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $9.5 Million - $11.8 Million	-109,285 Reduced 91.71%	9,880 $947,000
Q3 2020 Nov 16, 2020	SELL	$96.16 - $135.15 $8.56 Million - $12 Million	-89,040 Reduced 42.77%	119,165 $11.5 Million
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $5.22 Million - $8 Million	61,371 Added 41.8%	208,205 $25.4 Million
Q1 2020 May 15, 2020	BUY	$75.11 - $113.76 $1.32 Million - $1.99 Million	17,523 Added 13.55%	146,834 $12.7 Million
Q4 2019 Feb 14, 2020	SELL	$86.8 - $118.57 $6.52 Million - $8.9 Million	-75,062 Reduced 36.73%	129,311 $13.9 Million
Q3 2019 Nov 14, 2019	SELL	$83.82 - $101.5 $9.49 Million - $11.5 Million	-113,278 Reduced 35.66%	204,373 $18.4 Million
Q2 2019 Aug 14, 2019	BUY	$72.24 - $91.27 $11.4 Million - $14.5 Million	158,367 Added 99.42%	317,651 $26.8 Million
Q1 2019 May 15, 2019	SELL	$69.31 - $91.53 $3.55 Million - $4.69 Million	-51,239 Reduced 24.34%	159,284 $14 Million
Q4 2018 Feb 14, 2019	SELL	$68.32 - $124.36 $1.57 Million - $2.85 Million	-22,942 Reduced 9.83%	210,523 $15 Million
Q3 2018 Nov 14, 2018	BUY	$98.88 - $125.85 $1.63 Million - $2.07 Million	16,462 Added 7.59%	233,465 $28.7 Million
Q2 2018 Aug 14, 2018	BUY	$75.3 - $105.99 $5.02 Million - $7.06 Million	66,656 Added 44.33%	217,003 $21.3 Million
Q1 2018 May 15, 2018	BUY	$75.88 - $92.43 $3.36 Million - $4.09 Million	44,267 Added 41.73%	150,347 $12.5 Million
Q4 2017 Feb 14, 2018	BUY	$58.53 - $77.59 $5.96 Million - $7.9 Million	101,804 Added 2380.82%	106,080 $8.23 Million
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $205,119 - $262,033	4,276	4,276 $262,000

Others Institutions Holding NBIX

# of Institutions

626

Shares Held

94M

Call Options Held

632K

Put Options Held

621K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account